Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 28, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes and Transactions
The filing details several share transfers and sales executed by the GlaxoSmithKline Employee Trust ("GSK Trust") and the GlaxoSmithKline (US) Trust ("GSK US Trust") between February 22 and February 27, 2007:
- February 22: GSK Trust transferred 5,054 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- February 23: GSK Trust transferred 46,290 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- February 26: GSK Trust transferred 11,960 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- February 27:
- GSK US Trust sold 325 ADRs at $56.45 per ADR on behalf of the GlaxoSmithKline Performance Share Plan.
- GSK US Trust transferred 675 ADRs to participants in the GlaxoSmithKline Performance Share Plan.
- GSK Trust transferred 28,752 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- GSK Trust sold 5,250 Ordinary Shares at GBP 14.37 on behalf of the GlaxoSmithKline Performance Share Plan.
- GSK Trust transferred 8,250 Ordinary Shares to participants in the GlaxoSmithKline Performance Share Plan.
Management Commentary and Risks
The filing clarifies the nature of the trusts involved. The GSK Trust is a discretionary trust for employees or former employees of GlaxoSmithKline plc and its subsidiaries. The GSK US Trust is a grantor trust for employees or former employees of SmithKline Beecham Corporation and its subsidiaries. Directors Dr. J-P Garnier, Dr. M M Slaoui, and Mr. J S Heslop hold interests in the GSK Trust, while Dr. J-P Garnier and Dr. M M Slaoui hold interests in the GSK US Trust, in the same capacity as other employees. No specific risks, contingencies, or unusual items beyond these standard trust operations are disclosed.
Investor Verification Checklist
- Verify the total volume of shares transferred to the SmithKline Beecham Employee Share Option Plan 1991 across the reporting dates.
- Confirm the sale price of ADRs ($56.45) and Ordinary Shares (GBP 14.37) against market prices on the transaction dates.
- Review the specific roles of Directors Dr. J-P Garnier, Dr. M M Slaoui, and Mr. J S Heslop regarding their interests in the respective trusts.
- Note that this filing contains no financial performance data; refer to Form 20-F for revenue and profit metrics.